Trial · NCT01847092

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

NCT01847092, Phase 2, Completed, Ardelyx; results first posted 2020-05-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria. Trials, record NCT01847092. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01847092

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
NCT number: NCT01847092
Status: Completed
Phases: Phase 2
Enrollment: 154 participants, actual
Lead sponsor: Ardelyx
Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: AZD1722, Placebo
First posted: 2013-05-06
Last updated: 2020-05-27
Results first posted: 2020-05-27

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Changes in Urine Albumin to Creatinine Ratio (UACR)	Week 12	The difference between tenapanor and placebo in the change in UACR from baseline to the end of 12 weeks of treatment
Secondary	Change in Estimated Glomerular Filtration Rate (mL/Min/1.73 m2) From Baseline to Week 12 Endpoint	12 weeks

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Changes in Urine Albumin to Creatinine Ratio (UACR)	Week 12		mg/g	MEAN
SECONDARY	Change in Estimated Glomerular Filtration Rate (mL/Min/1.73 m2) From Baseline to Week 12 Endpoint	12 weeks		mL/min/1.73 m2	LEAST_SQUARES_MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Changes in Urine Albumin to Creatinine Ratio (UACR)	AZD1722	-64.6	Standard Deviation 898.4	mg/g
Changes in Urine Albumin to Creatinine Ratio (UACR)	Placebo	104.8	Standard Deviation 668.0	mg/g
Change in Estimated Glomerular Filtration Rate (mL/Min/1.73 m2) From Baseline to Week 12 Endpoint	AZD1722	-2.8	Standard Deviation 1.21	mL/min/1.73 m2
Change in Estimated Glomerular Filtration Rate (mL/Min/1.73 m2) From Baseline to Week 12 Endpoint	Placebo	-2.7	Standard Deviation 1.19	mL/min/1.73 m2

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	AZD1722	77
Overall Study	STARTED	Placebo	77
Overall Study	COMPLETED	AZD1722	51
Overall Study	COMPLETED	Placebo	66
Overall Study	NOT COMPLETED	AZD1722	26
Overall Study	NOT COMPLETED	Placebo	11

Source ClinicalTrials.gov

Adverse events8

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Diarrhea	Gastrointestinal disorders	AZD1722	45	77	45
other	Diarrhea	Gastrointestinal disorders	Placebo	4	77	4
serious	Hyperkalemia	Investigations	AZD1722	2	77	2
serious	Hyperkalemia	Investigations	Placebo	1	77	1
serious	Deep Vein Thrombosis	Blood and lymphatic system disorders	AZD1722	1	77	1
serious	Deep Vein Thrombosis	Blood and lymphatic system disorders	Placebo	0	77	0
serious	Cardiac failure congestive	Cardiac disorders	AZD1722	0	77	0
serious	Cardiac failure congestive	Cardiac disorders	Placebo	1	77	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	AZD1722	0	77
Total, all-cause mortality	Placebo	0	77
Total, other adverse events	AZD1722	45	77
Total, other adverse events	Placebo	4	77
Total, serious adverse events	AZD1722	3	77
Total, serious adverse events	Placebo	2	77

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
AZD1722 vs Placebo: deaths from any cause	Trial comparisons
AZD1722 vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01847092

GET https://conductscience.org/api/trials/v1/NCT01847092/registered

API reference For AI assistants